Interventions. Copies: This document is available on the World Wide Web sites of the
American College of Cardiology (www. cardiosource. org), the American Heart Association …

The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

The recommendations listed in this CPG are, whenever possible, evidence based. An
extensive evidence review was conducted through October 2012, and other selected …

The recommendations listed in this CPG are, whenever possible, evidence based. An
extensive evidence review was conducted through October 2012, and other selected …

Background Percutaneous coronary intervention (PCI)-related myonecrosis is frequent and
can affect the long-term prognosis of patients. To our knowledge, ticagrelor has not been …

Background—Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist. This is
the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor using …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted through November 2010, as well as selected …

Background Treatment with the direct thrombin inhibitor bivalirudin, as compared with
heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while …

Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …

The ACC/AHA Task Force on Practice Guidelines was formed to gather information and
make recommendations about appropriate use of technology for the diagnosis and …